Jeffrey Schwartz - May 24, 2023 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Director
Signature
/s/ Jeffrey Schwartz
Stock symbol
SWTX
Transactions as of
May 24, 2023
Transactions value $
$0
Form type
4
Date filed
5/25/2023, 05:04 PM
Previous filing
May 5, 2023
Next filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Award $0 +4.65K +78.46% $0.00 10.6K May 24, 2023 Direct F1
holding SWTX Common Stock 3.08M May 24, 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Award $0 +13.8K $0.00 13.8K May 24, 2023 Common Stock 13.8K $32.27 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
F2 This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
F3 The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
F4 Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.